Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 18/20 | 0.53 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.52 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.52 |
| ▸ | NPY4R | P50391 | 3/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29299989 | 0.94 | NPY1R (0.50) | NPY1RNPFFR1NPFFR2NPY5RNPY4R | |
| SCHEMBL29299990 | 0.89 | NPY1R (0.54) | NPY1RNPFFR1NPFFR2NPY5RNPY4R | |
| SCHEMBL29299994 | 0.89 | NPY1R (0.54) | NPY1RNPFFR1NPFFR2NPY5RNPY4R | |
| SCHEMBL31652831 | 0.85 | NPY1R (0.41) | NPY1RNPFFR1NPFFR2NPY5RNPY4R | |
| SCHEMBL650331 | 0.84 | NPY1R (0.72) | NPY1RNPFFR1NPFFR2NPY5RNPY4R | |
| SCHEMBL7751683 | 0.84 | NPY1R (0.62) | NPY1RNPFFR1NPFFR2NPY5RNPY4R | |
| SCHEMBL7751915 | 0.83 | NPY1R (0.60) | NPY1RNPFFR1NPFFR2NPY5RNPY4R | |
| SCHEMBL8636365 | 0.81 | NPY1R (0.63) | NPY1RNPFFR1NPFFR2NPY5RNPY4R | |
| SCHEMBL7753042 | 0.81 | NPY1R (0.70) | NPY1RNPFFR1NPFFR2NPY5RNPY4R | |
| SCHEMBL29299991 | 0.81 | NPY1R (0.54) | NPY1RNPFFR1NPFFR2NPY5RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | NPY1R 1/4885NPFFR1 21/4885NPFFR2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.